乳腺癌女性中异喹胍的多态性氧化作用。

Polymorphic oxidation of debrisoquine in women with breast cancer.

作者信息

Ladero J M, Benítez J, Jara C, Llerena A, Valdivielso M J, Muñoz J J, Vargas E

机构信息

Department of Medicine, University Complutense, Madrid, Spain.

出版信息

Oncology. 1991;48(2):107-10. doi: 10.1159/000226906.

DOI:10.1159/000226906

PMID:1997931

Abstract

Oxidative polymorphism of debrisoquine (DBQ) was determined in 98 women with breast cancer (mean age 59.2 years, SD 10.7; 18 were premenopausal when diagnosed), and in 446 healthy control women (mean age 25.4 years, SD 9.15). All of them were free of drug interactions with oxidation of DBQ. Ten patients (10.2%), all of them postmenopausal when diagnosed, and 423 controls (5.2%), with values for metabolic ratio of DBQ greater than 12.6, were classified as poor metabolizers (PM) of DBQ (p = 0.006). Relative risk for developing breast cancer among women with PM phenotype was 2.09 (95% confidence limits 0.97-4.48). The PM status of DBQ might be a secondary risk factor for breast cancer in postmenopausal women.

摘要

在98名乳腺癌女性患者（平均年龄59.2岁，标准差10.7；其中18名在确诊时处于绝经前）和446名健康对照女性（平均年龄25.4岁，标准差9.15）中测定了异喹胍（DBQ）的氧化多态性。她们均不存在与DBQ氧化相关的药物相互作用。10名患者（10.2%），均在确诊时处于绝经后，以及423名对照者（5.2%），其DBQ代谢率大于12.6，被归类为DBQ慢代谢者（PM）（p = 0.006）。PM表型女性患乳腺癌的相对风险为2.09（95%置信区间0.97 - 4.48）。DBQ的PM状态可能是绝经后女性患乳腺癌的一个次要风险因素。